Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/25273| Title: | Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. | Austin Authors: | Chételat, Gaël;Arbizu, Javier;Barthel, Henryk;Garibotto, Valentina;Law, Ian;Morbelli, Silvia;van de Giessen, Elsmarieke;Agosta, Federica;Barkhof, Frederik;Brooks, David J;Carrillo, Maria C;Dubois, Bruno;Fjell, Anders M;Frisoni, Giovanni B;Hansson, Oskar;Herholz, Karl;Hutton, Brian F;Jack, Clifford R;Lammertsma, Adriaan A;Landau, Susan M;Minoshima, Satoshi;Nobili, Flavio;Nordberg, Agneta;Ossenkoppele, Rik;Oyen, Wim J G;Perani, Daniela;Rabinovici, Gil D;Scheltens, Philip;Villemagne, Victor L ;Zetterberg, Henrik;Drzezga, Alexander | Affiliation: | Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark Institute of Neuroscience, Newcastle University, Newcastle, UK Normandie Université, Université de Caen, Institut National de la Santé et de la Recherche Médicale, Unité 1237, Groupement d'Intérêt Public Cyceron, Caen, France. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at University College London, London, UK Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia Department of Nuclear Medicine, University of Navarra, Clinica Universidad de Navarra, Pamplona, Spain Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals and NIMTlab, Geneva University, Geneva, Switzerland Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark Nuclear Medicine Unit, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Istituto di Ricovero e Cura a Carattere, San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Institutes of Neurology and Healthcare Engineering, University College London, London, UK Alzheimer's Association, Chicago, IL, USA Centre des Maladies Cognitives et Comportementales, University Hospital of Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne-Université, Paris, France Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, Norway, Oslo; Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway Memory Clinic, Department of Rehabilitation and Geriatrics, Geneva University and University Hospitals, Geneva, Switzerland Clinical Memory Research Unit, Lund University, Malmö, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden Wolfson Molecular Imaging Centre, Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK Institute of Nuclear Medicine, University College London, London, UK Department of Radiology, Mayo Clinic, Rochester, MN, USA Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT, USA UO Clinica Neurologica, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Child and Mother Health, University of Genoa, Genova, Italy Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden Department of Neurology, Alzheimer Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Clinical Memory Research Unit, Lund University, Lund, Sweden Humanitas University and Humanitas Clinical and Research Center, Department of Nuclear Medicine, Milan, Italy; Rijnstate, Department of Radiology and Nuclear Medicine, Arnhem, Netherlands; Radboud UMC, Department of Radiology and Nuclear Medicine, Nijmegen, Netherlands Vita-Salute San Raffaele University, Nuclear Medicine Unit, San Raffaele Hospital, Division of Neuroscience San Raffaele Scientific Institute, Milan, Italy Departments of Neurology, Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA Department of Neurology, Alzheimer Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; German Center for Neurodegenerative Diseases, Bonn-Cologne, Germany; Institute of Neuroscience and Medicine, Molecular Organization of the Brain, Forschungszentrum Jülich, Germany Medicine (University of Melbourne) Molecular Imaging and Therapy |
Issue Date: | Nov-2020 | Date: | 2020-11 | Publication information: | The Lancet. Neurology 2020; 19(11): 951-962 | Abstract: | Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and 18F-fluorodeoxyglucose (18F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations because conclusive evidence is missing. Following an expert panel discussion, we reached an agreement on the specific use of the individual biomarkers, based on available evidence and clinical expertise. We propose a diagnostic algorithm with optimal timepoints for these PET biomarkers, also taking into account evidence from other biomarkers, for early and differential diagnosis of neurodegenerative diseases that can lead to dementia. We propose three main diagnostic pathways with distinct biomarker sequences, in which amyloid-PET and 18F-FDG-PET are placed at different positions in the order of diagnostic evaluations, depending on clinical presentation. We hope that this algorithm can support diagnostic decision making in specialist clinical settings with access to these biomarkers and might stimulate further research towards optimal diagnostic strategies. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/25273 | DOI: | 10.1016/S1474-4422(20)30314-8 | Journal: | The Lancet. Neurology | PubMed URL: | 33098804 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.